GlassScriptPhysician profile
Jake Leslie Bennett
NPI 1063093425
$1,702.11
in general payments reported to CMS, 2019-2025
18 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $405 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.79 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $337.40 | 2025 | |
| Dynavax Technologies Corporation | $159.32 | 2024-2025 | Heplisav-B |
| Lilly USA, LLC | $133.09 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $103.13 | 2024-2025 | Voquezna |
| Pfizer INC. | $93.73 | 2024-2025 | |
| Exact Sciences Corporation | $85.60 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $66.31 | 2024-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $62.16 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $52.12 | 2024 | |
| Boston Scientific Corporation | $51.12 | 2024-2025 | Intracept, Watchman Access System |
| Glaxosmithkline, LLC. | $47.38 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $46.48 | 2025 | |
| Merck Sharp & Dohme LLC | $26.22 | 2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.13 | 2025 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.96 | 2025 | Caplyta |
| Dexcom, INC. | $22.89 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $20.28 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.